0
Deep & Emerging Tech·May 22, 2026·1 min read

FDA clears Gilead's hepatitis D drug, four years after prior rejection

Share

Four years after a manufacturing and distribution-related rejection, Gilead finally gets Hepcludex cleared — the bottleneck wasn’t biology, it was CMC and supply. If you’re in therapeutics, treat manufacturing quality and regulatory operations as core IP, not back-office functions you can fix later.

Deep & Emerging Tech

How Iranian threat actor Nimbus Manticore used techniques like AI-assisted malware development and SEO poisoning to target companies during the US-Iran war (Check Point Research)

State-linked actors using AI-assisted malware and SEO poisoning during wartime is the new baseline—offense is now automated, scalable, and tightly coupled to real-world conflict. Assume your brand, search footprint, and download flows are active battlefields and harden them like you would a payments system.